Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.59 |
| ▸ | DRD3 | P35462 | 8/20 | 0.51 |
| ▸ | DRD2 | P14416 | 7/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024270 | 0.96 | HRH3 (0.61) | HRH3DRD3DRD2HRH4AKR1C3 | |
| SCHEMBL1378166 | 0.90 | HRH3 (0.58) | HRH3DRD3DRD2HRH4 | |
| SCHEMBL5023202 | 0.85 | HRH3 (0.62) | HRH3DRD3DRD2 | |
| SCHEMBL1376627 | 0.85 | HRH3 (0.74) | HRH3DRD3DRD2 | |
| SCHEMBL5017035 | 0.84 | HRH3 (0.76) | HRH3DRD3DRD2 | |
| SCHEMBL1379016 | 0.84 | HRH3 (0.76) | HRH3DRD3DRD2 | |
| SCHEMBL5027430 | 0.84 | HRH3 (0.56) | HRH3DRD3DRD2HRH4AKR1C3 | |
| SCHEMBL5023174 | 0.83 | HRH3 (0.63) | HRH3DRD3DRD2HRH4KMT2A | |
| SCHEMBL5025829 | 0.83 | HRH3 (0.60) | HRH3DRD3DRD2HRH4AKR1C3 | |
| SCHEMBL5023626 | 0.83 | HRH3 (0.61) | HRH3DRD3DRD2HRH4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761519-B1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-7361682-B2 | Indole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1761519-A1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123716-A1 | INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HOFFMANN-LA ROCHE INC. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282864-A1 | Indole derivatives as H3 inverse agonists | HRH3, HRH4, ADRB1 | HRH3 1/4885DRD3 206/4885DRD2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.